

# Product Statement

# Fair Value Assessment Outcome & Target Market Information

This document¹ has been produced by Travelers Europe in accordance with our regulatory responsibilities as a Product Manufacturer of UK General Insurance products. It is intended for use by our Distributors and not for customers or operational staff.

For more information, please speak to your usual Travelers representative.

<sup>&</sup>lt;sup>1</sup> This document is based on the Product Value – Information Exchange Template, version 8 November 2021 (LMA9197), developed by the following trade associations for use by all market participants to meet the requirements of the Financial Conduct Authority's product governance rules relating to information exchange: the British Insurance Brokers' Association (BIBA), the London and International Insurance Brokers' Association (LIIBA), the Lloyd's Market Association (LMA), the International Underwriting Association (IUA), the Managing General Agent's Association (MGAA) and the Association of British Insurers (ABI).

Travelers Insurance Company Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Registered Office: One Creechurch Place, Creechurch Lane, London EC3A 5AF. Registered in England 01034343.

Travelers Insurance Designated Activity Company is regulated and authorised by the Central Bank of Ireland and its UK branch is regulated by the Prudential Regulatory Authority and the Financial Conduct Authority. Travelers Insurance Designated Activity Company is a private company limited by shares. Registered in Ireland with registration number 620416. Registered Office: Third Floor, Block 8, Harcourt Centre, Charlotte Way, Dublin 2, Ireland UK Branch Office: One Creechurch Place, Creechurch Lane, London EC3A 5AF.

# **Product Value - Information Exchange Template**

Carrier name	Travelers Insurance Company Limited (TICL)/ Travelers Insurance Designated Activity Company UK Branch (TIDAC UK Branch
Broker name	As stated in TOBA
Product name	Medical Technology
Reference/UMR [Binder]	n/a
Reference [Class of	TICL: TRV3052 UK Policy Code 2223 09.19
Business]	TIDAC UK Branch: TRV3053 09.21 Policy Code 2223 09.19
Date	Qtr 3 2024

Manufacturer Information
Product information

The Medical Technology product provides an insurance and risk management solution aimed at organisations that enhance, improve medical health and that have a therapeutic, medical, surgical and preventative medical benefit for humans and or animals. The policy combines selectable property, liability, professional liability and cyber covers into one comprehensive wording.

This product is structured as a package product with the option to select optional covers which enables the client to build a commercial insurance solution to suit their needs. The product provides the following covers:

- Property damage
- Business interruption
- Medical technology, property damage and business interruption combined section
- Computer and machinery breakdown
- Terrorism
- Employer's liability
- Public and products liability
- Medical technology professional indemnity and cyber

The product includes the following optional covers:

- Money and personal accident (assault)
- Goods in transit
- Product recall
- Legal expenses
- Outstanding debit balances

In accordance with the FCA PROD4 rules, a product review and fair value assessment has been completed for this product.

The product has been subject to Travelers' full product review process and signed off by our authorised approvers as representing fair value to customers and may continue to be marketed and distributed.

This product meets the needs detailed within the Target Market Statement.

The product provides fair value to customers and is working as designed. Key metrics on usage and product value are monitored; the product is suitable for use and we have not identified any barriers to claims

Our assessment of fair value includes review of the following management information (where available – not all data will be available for new products) as well as any other relevant insight:

- Average Premium
- Average Claims Pay-out
- Loss Ratio
- Policy Cancellations
- Claim Declinatures as % of Total Claims
- Claims Acceptance Rate
- Number of Complaints

• Complaints as % of Claims

## Target market

The Medical Technology product is designed for organisations that enhance, improve medical health and that have a therapeutic, medical, surgical and preventative medical benefit for humans and or animals.

Proposition is tailored to meet the needs of companies in the following areas:

#### Biotechnology

- Research and development drug discovery institutes
- Contract research organisations

(Minimum premium >GBP5k)

#### **Medical Devices**

- Design, manufacture and distribution of diagnostic, monitoring or treatment devices (Class I, Class II, Class IIa products)
- Medical software companies
- Contract manufacturing organisations

(Minimum premium >GBP10k)

# Types of customer for whom the product would be unsuitable

It is not suitable for companies:

- Manufacturing and/or selling pharmaceutical, cosmeceutical &/or nutraceutical products
- Manufacturing and/or selling permanently implantable [within the body] medical devices
- Selling, supplying, leasing or licencing product that has not obtained the required regulatory or government approval
- Requiring cover for Clinical Trials
- Requiring cover for Medical Malpractice &/or Abuse coverage

It is not suitable for other trade sectors for which there are more appropriate insurance solutions.

# Any notable exclusions or circumstances where the product will not respond

As is commonplace for Insurance products for this sector there are a number of general exclusions including but not limited to:

- War and allied risks
- Terrorism (except where covered under the Terrorism section)
- Asbestos
- Silica
- Pollution
- Cyber Risks (except where covered by the Technology Professional Indemnity and Cyber section)
- Punitive and other non-compensatory damages

Other section specific exclusions will apply, depending on the coverage selections made by the customer. Policy excesses and cover limits are assessed on a risk by risk basis, taking into account market standards, and selected by the customer.

This product statement does not alter, in any way, the cover under the policy.

## Other information which may be relevant to distributors

This document is to be read in conjunction with the full policy wording.

The distribution strategy is considered appropriate for the target market with customers having the option to purchase these products through a distributor of their choice. This product may be sold by suitably skilled authorised persons:

• on an advised basis

To ensure the customer receives fair value for this product and that they are able to make an informed choice:

- The customer's demand and needs must be assessed to ensure the product is appropriate,
- significant or unusual exclusions should be highlighted,
- care must be taken to ensure no duplicate cover exists or is created by an add-on,
- available add-ons and optional extras should be highlighted with the same emphasis as the main sections of
- commission, fees or charges passed onto the customer must be proportionate to the service provided.

Date Fair Value assessment completed	Quarter 3 2024
Expected date of next assessment	Quarter 3 2025